Ranibizumab - CISMeF

Preferred Label : Ranibizumab;

NCIt synonyms : Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor) Fab Fragment (Human-Mouse Monoclonal rhuFab V2 Gamma1 Chain), Disulfide With Human-Mouse Monoclonal rhuFab V2 Light Chain;

NCIt definition : A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha. Ranibizumab binds to VEGF alpha and inhibits VEGF alpha binding to its receptors, VEGFR1 and VEGFR2, thereby preventing the growth and maintenance of tumor blood vessels. The molecular weight of this agent (48 kD) is much smaller than the molecular weight of bevacizumab (MW 149 kD), allowing complete penetration of the retina and the subretinal space following intravitreal injection. In contrast to other anti-VEGF aptamers such as pegaptanib, ranibizumab has a high specificity and affinity for all soluble human isoforms of VEGF.;

UNII : ZL1R02VT79;

CAS number : 347396-82-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 347396-82-1 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Lucentis;

Details

Origin ID

C67562;

UMLS CUI

C1566537;

Automatic exact mappings (from CISMeF team)
- Ranibizumab [ICD-11 Extension code]
CISMeF manual mappings
- Ranibizumab [MeSH Descriptor]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Product containing ranibizumab (medicinal product) [SNOMED CT concept]
- Ranibizumab [MeSH Descriptor]
- Ranibizumab (substance) [SNOMED CT concept]
- ranibizumab [ATC Code]
- ranibizumab [International Nonproprietary Name]
- ranibizumab [MeSH concept]
Validated automatic mappings to BTNT
- ranibizumab [ATC Code]
chemical_or_drug_affects_cell_type_or_tissue
- Retina [NCIt concept]
chemical_or_drug_affects_gene_product
- Vascular Endothelial Growth Factor A [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Growth Factor Inhibition [NCIt concept]
- Inhibition of Cell Proliferation [NCIt concept]
- Negative Regulation of Angiogenesis [NCIt concept]
- Signal Transduction Inhibition [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Vascular Endothelial Growth Factor A [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients